Effect of prostate manipulation on the serum levels of complexed prostate‐specific antigen and total prostate‐specific antigen

Long, Ronan M.; Giri, Subhasis; Diver, Sean; Duddy, Lorna; Mckeown, Declan; Moran, K. T.

doi:10.1111/j.1442-2042.2006.01445.x

Cited by 9 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, rise in PSA correlates to the invasiveness of the procedure [61]. Also, PSA levels are detected over a period ranging from few hours to several weeks after treatment [62–64]. MLu - PDT causes a short term increase in serum PSA levels, which may be due to cellular damage, leading to release of PSA in circulation [64].…”

Section: Motexafin Lutetiummentioning

confidence: 99%

Photosensitizers in prostate cancer therapy

2017

View full text Add to dashboard Cite

The search for new therapeutics for the treatment of prostate cancer is ongoing with a focus on the balance between the harms and benefits of treatment. New therapies are being constantly developed to offer treatments similar to radical therapies, with limited side effects. Photodynamic therapy (PDT) is a promising strategy in delivering focal treatment in primary as well as post radiotherapy prostate cancer. PDT involves activation of a photosensitizer (PS) by appropriate wavelength of light, generating transient levels of reactive oxygen species (ROS). Several photosensitizers have been developed with a focus on treating prostate cancer like mTHPC, motexafin lutetium, padoporfin and so on. This article will review newly developed photosensitizers under clinical trials for the treatment of prostate cancer, along with the potential advantages and disadvantages in delivering focal therapy.

show abstract

Section: Motexafin Lutetiummentioning

confidence: 99%

Photosensitizers in prostate cancer therapy

2017

View full text Add to dashboard Cite

show abstract

“…(20-26). The rise in PSA correlates to the invasiveness of procedure (20), and elevated PSA levels are generally detected over a period ranging from less than 1 h to several weeks after the procedure (21-23, 25). The biochemical success of prostate treatment is typically measured through the extent of PSA reduction subsequent to its initial therapy-induced spike (22, 25).…”

Section: Introductionmentioning

confidence: 99%

Motexafin Lutetium-Photodynamic Therapy of Prostate Cancer: Short- and Long-Term Effects on Prostate-Specific Antigen

Patel

Mick²,

Finlay

et al. 2008

Clinical Cancer Research

109

View full text Add to dashboard Cite

Purpose: The time course of serum prostate-specific antigen (PSA) response to photodynamic therapy (PDT) of prostate cancer was measured. Experimental Design: Seventeen patients were treated in a phase I trial of motexafin lutetium-PDT. PDT dose was calculated in each patient as the product of the ex vivo measured pre-PDT photosensitizer level and the in situ measured light dose. Serum PSA level was measured within 2 months before PDT (baseline), and at day 1; weeks 1to 3; months 1, 2, and 3; months 4 to 6; and months 7 to 11after PDT. Results: At 24 hours after PDT, serum PSA increased by 98% F 36% (mean F SE) relative to baseline levels (P = 0.007). When patients were dichotomized based on median PDT dose, those who received high PDT dose showed a 119% F 52% increase in PSA compared with a 54% F 27% increase in patients treated at low PDT dose. Patients treated with high versus low PDT dose showed a median biochemical delay of 82 versus 43 days (P = 0.024), with biochemical delay defined as the length of time between PDT and a nonreversible increase in PSA to a value greater than or equal to baseline. Conclusions: Results show PDT to induce large, transient increases in serum PSA levels. Patients who experienced high PDT dose showed greater short-term increase in PSA and a significantly more durable PSA response (biochemical delay). These data strongly promote the need for individualized delivery of PDTdose and assessment of treatment effect in PDTof prostate cancer. Information gained from such patient-specific measurements could facilitate the introduction of multiple PDTsessions in patients who would benefit.

show abstract

“…Data from prior studies evaluating PSA change in relation to Table 3 Statistical comparison of total serum PSA levels at 0 and 24 h post CPE cystoscopy have shown variable results, as serum PSA level may either increase or remain the same following cystoscopy. We believe, while it is well accepted, that no urologist may consider an elevated PSA after CPE to be pathological; nevertheless, there is scarcity in published studies evaluating the precise effect of rigid cystoscopy on serum PSA levels, as a recent review of literature suggests that the serum PSA level may increase or remain unaltered following rigid cystoscopy (Table 4) [18,[25][26][27][28][29][30][31][32][33][34]. While the effect of rigid cystoscopy on serum PSA has not been clearly defined in the published literature (Table 4), in our study, we observed a significant rise in the serum PSA levels both at 1 and 24 h following cystoscopy.…”

Section: Discussionmentioning

confidence: 99%